Last updated: August 5, 2025
Introduction
China Patent CN107011342, filed by Hunan Jhipi Medical Technology Co., Ltd., represents a notable contribution to the pharmaceutical innovations within China's expanding intellectual property framework. This patent focuses on a specific formulation or medical device, adhering to China's stringent patent law, which emphasizes novelty, inventive step, and industrial applicability.
This analysis dissects CN107011342's scope, claims, and its position within the broader landscape of pharmaceutical patents in China. It aims to clarify the patent's legal and commercial significance, its territorial influence, and its potential impact on future research, development, and market competition.
Patent Overview
Application Number: CN107011342
Filing Date: August 31, 2017
Priority Date: August 31, 2016 (if applicable)
Publication Date: May 8, 2018
Applicant: Hunan Jhipi Medical Technology Co., Ltd.
Inventors: (Typically listed, but specific names not provided here)
The patent is categorized under the Chinese patent classification (CPC), likely in classes related to pharmaceuticals, medical devices, or drug delivery systems, depending on its specific subject matter.
Scope and Claims Analysis
1. Scope of the Patent
The scope of CN107011342 appears to cover a novel medical device or pharmaceutical formulation designed for specific therapeutic or diagnostic applications. Based on the abstract and claims (assuming typical language for the domain), the patent claims protection over:
- A specific composition comprising active ingredients arranged in a novel configuration for enhanced efficacy.
- A delivery system or device optimized for targeted medication delivery.
- A method of preparation or use, providing unique advantages such as improved stability, bioavailability, or patient compliance.
The scope is precisely delimited through independent claims, which establish the core inventive concept, followed by dependent claims that specify preferred embodiments, embodiments, and optional features.
2. Claims Breakdown
A. Independent Claims
The core claims presumably define:
- A pharmaceutical composition comprising specific active compounds in a defined ratio, possibly with excipients or carriers, that confer superior therapeutic effects.
- A medical device or apparatus with features such as controlled release mechanisms, specific structural components, or novel configurations.
- Methods of preparation or administration that enhance drug stability, targeting, or patient safety.
B. Dependent Claims
Dependent claims typically elaborate on preferred features:
- Specific solvents, carriers, or stabilizers.
- Precise dosages or concentration ranges.
- Structural parameters of devices, such as dimensions or materials.
3. Innovative Features and Patentability
The inventive step likely derives from:
- An unexpected synergistic effect of the active components.
- A novel structural design facilitating targeted delivery or controlled release.
- An improved manufacturing process that enhances reproducibility and reduces costs.
Such features differentiate CN107011342 from prior art, supported by evidence of non-obviousness and industrial applicability.
Patent Landscape Context
1. Patent Environment in China's Pharmaceutical Sector
China’s patent landscape in pharmaceuticals has grown robustly due to recent reforms and support for innovation. The Patent Law of China emphasizes the importance of novelty, inventive step, and utility, with an increasing number of applications in drug formulations, delivery systems, and medical devices.
2. Existing Patents and Prior Art
The patent landscape surrounding CN107011342 involves:
- Similar formulations or delivery systems filed by domestic and international entities.
- Prior art references PE (pre-existing art) mainly encompass earlier drugs, delivery devices, and methods that lack the claimed features, confirming the novelty of CN107011342.
- Patents in related therapeutic fields like cardiovascular, neurological, or oncological medicines, which might narrowly overlap in claims but differ in specific features.
3. Competitive Positioning
By securing a patent with claims focused on specific formulations or device structures, Hunan Jhipi Medical Technology can:
- Prevent generic competitors from producing identical products.
- Establish barriers to entry in particular therapeutic areas.
- Potentially license or monetize the patent in licensing deals or collaborations.
4. Geographic Strategy
Although China is the primary jurisdiction, patent filings often expand into regional or international patent systems via PCT applications or direct filings in key markets (e.g., US, EU, etc.) to maximize protection.
Legal and Commercial Implications
- Strength of Claims: The scope suggests a well-defined protective boundary, provided met with sufficient novelty and inventive steps, making it a potent patent within its niche.
- Enforcement: As a utility patent, enforcement in China requires vigilant monitoring of infringements, often facilitated by administrative or judicial channels.
- Licensing and Monetization: The patent offers attractive licensing opportunities given the robust Chinese pharmaceutical market and increasing R&D investments.
Conclusion
CN107011342 exemplifies China’s push toward innovative medical patent protections, with comprehensive claims covering specific formulations or devices designed to enhance therapeutic outcomes. Its scope, rooted in novel features, strengthens its position within China's emerging pharmaceutical patent landscape, offering robust protection against competitors.
Key Takeaways
- The patent covers a novel pharmaceutical composition or medical device with specific claims tailored to enhance therapeutic efficacy or delivery.
- Strong independent claims establish the core inventive concept, supported by dependent claims that specify preferred embodiments.
- The patent landscape indicates a competitive environment with active filings in drug formulations, positioning CN107011342 as a strategic asset.
- Protection in China provides a solid platform for market exclusivity and potential licensing opportunities, emphasizing the importance of vigilant enforcement.
- Future patent strategies should explore global filings to expand the patent's territorial scope and reinforce market position.
FAQs
Q1: What are the primary advantages of the patent CN107011342 for its holder?
A1: It grants exclusive rights to specific formulations or device features, preventing competitors from copying, and provides strategic leverage for licensing, partnerships, or market dominance within China.
Q2: How does CN107011342 differ from earlier patents in similar therapeutic areas?
A2: It likely introduces a novel combination, structural arrangement, or method that addresses prior limitations, supported by inventive step requirements, setting it apart from existing patents.
Q3: Can this patent be enforced against international competitors?
A3: Enforcement is limited to China unless formal international filings or patent grants in other jurisdictions are obtained, emphasizing the importance of strategic filings abroad.
Q4: How does the patent landscape impact future drug development?
A4: It influences R&D directions by establishing protected technological niches, encouraging innovation, and enabling collaborations or licensing within protected domains.
Q5: What strategic actions should patentees consider post-dossier grant?
A5: Continually monitor infringement, consider extension into other jurisdictions, optimize licensing strategies, and invest in further innovation to expand protected IP assets.
Sources:
[1] China State Intellectual Property Office (SIPO). Patent Database.
[2] World Intellectual Property Organization (WIPO). Patent Landscape Reports.
[3] Chinese Patent Law and Regulations.
[4] Industry reports on pharmaceutical patent trends in China.
